What do the newer inotropic drugs have to offer? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-02

AUTHORS

Shigetake Sasayama

ABSTRACT

Intensive interest and passion have been generated in the search for orally effective inotropes over the past few decades. Several extensive clinical evaluations of these agents have now been completed. Both beta-adrenergic agonists and phosphodiesterase inhibitors that exert cardiotonic action by increasing intracellular cyclic adenosine monophosphate produced dramatic short-term hemodynamic benefits in patients with advanced heart failure. However, patients who received long-term treatment with these agents had unfavorable outcomes, including a higher mortality and morbidity rate, and deleterious side effects. The principal mechanisms responsible for the limitations in its usefulness in long-term therapy may be related to increased energy expenditure and potential arrhythmogenic effects. In contrast to these pessimistic views, one quinolinone derivative has been shown to exert a positive inotropic action without a chronotropic effect. Patients with mild heart failure responded favorably to this agent in long-term therapy. The lack of an increase in heart rate might be the cause of this salutary effect. Concerns regarding the possible improvement in the prognosis of patients with heart failure due to the use of positive inotropic therapy still continue. More... »

PAGES

15-18

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00050911

DOI

http://dx.doi.org/10.1007/bf00050911

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049995369

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1576092


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiotonic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Toyama", 
          "id": "https://www.grid.ac/institutes/grid.267346.2", 
          "name": [
            "Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sasayama", 
        "givenName": "Shigetake", 
        "id": "sg:person.0771215563.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771215563.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1161/01.cir.82.3.774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003895734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01857748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012082941", 
          "https://doi.org/10.1007/bf01857748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01857748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012082941", 
          "https://doi.org/10.1007/bf01857748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.69.2.298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016834176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.71.5.963", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049494226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)91517-e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053360172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(90)91517-e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053360172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078806679", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079793544", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1992-02", 
    "datePublishedReg": "1992-02-01", 
    "description": "Intensive interest and passion have been generated in the search for orally effective inotropes over the past few decades. Several extensive clinical evaluations of these agents have now been completed. Both beta-adrenergic agonists and phosphodiesterase inhibitors that exert cardiotonic action by increasing intracellular cyclic adenosine monophosphate produced dramatic short-term hemodynamic benefits in patients with advanced heart failure. However, patients who received long-term treatment with these agents had unfavorable outcomes, including a higher mortality and morbidity rate, and deleterious side effects. The principal mechanisms responsible for the limitations in its usefulness in long-term therapy may be related to increased energy expenditure and potential arrhythmogenic effects. In contrast to these pessimistic views, one quinolinone derivative has been shown to exert a positive inotropic action without a chronotropic effect. Patients with mild heart failure responded favorably to this agent in long-term therapy. The lack of an increase in heart rate might be the cause of this salutary effect. Concerns regarding the possible improvement in the prognosis of patients with heart failure due to the use of positive inotropic therapy still continue.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00050911", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097576", 
        "issn": [
          "0920-3206", 
          "1573-7241"
        ], 
        "name": "Cardiovascular Drugs and Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "What do the newer inotropic drugs have to offer?", 
    "pagination": "15-18", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ee294e3447a3c5f1f42da02524f11b0930a3ea0ebfc73f7c6b6adfde09aac546"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1576092"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8712220"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00050911"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049995369"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00050911", 
      "https://app.dimensions.ai/details/publication/pub.1049995369"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130831_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00050911"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00050911'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00050911'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00050911'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00050911'


 

This table displays all metadata directly associated to this object as RDF triples.

105 TRIPLES      21 PREDICATES      40 URIs      25 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00050911 schema:about N164c33c229ac497cad11f74fdf7fb7fc
2 N4a13a1f9259b40689669825bf4f2e8fd
3 N94fb53b4a307446e8a9adf4a5c07f9a3
4 Ne14a1fcdb5c242cebc66d2903daec5b0
5 anzsrc-for:11
6 anzsrc-for:1102
7 schema:author N4c7ecb40a2524a6784e33091e72fb4da
8 schema:citation sg:pub.10.1007/bf01857748
9 https://app.dimensions.ai/details/publication/pub.1078806679
10 https://app.dimensions.ai/details/publication/pub.1079793544
11 https://doi.org/10.1016/0140-6736(90)91517-e
12 https://doi.org/10.1161/01.cir.69.2.298
13 https://doi.org/10.1161/01.cir.71.5.963
14 https://doi.org/10.1161/01.cir.82.3.774
15 schema:datePublished 1992-02
16 schema:datePublishedReg 1992-02-01
17 schema:description Intensive interest and passion have been generated in the search for orally effective inotropes over the past few decades. Several extensive clinical evaluations of these agents have now been completed. Both beta-adrenergic agonists and phosphodiesterase inhibitors that exert cardiotonic action by increasing intracellular cyclic adenosine monophosphate produced dramatic short-term hemodynamic benefits in patients with advanced heart failure. However, patients who received long-term treatment with these agents had unfavorable outcomes, including a higher mortality and morbidity rate, and deleterious side effects. The principal mechanisms responsible for the limitations in its usefulness in long-term therapy may be related to increased energy expenditure and potential arrhythmogenic effects. In contrast to these pessimistic views, one quinolinone derivative has been shown to exert a positive inotropic action without a chronotropic effect. Patients with mild heart failure responded favorably to this agent in long-term therapy. The lack of an increase in heart rate might be the cause of this salutary effect. Concerns regarding the possible improvement in the prognosis of patients with heart failure due to the use of positive inotropic therapy still continue.
18 schema:genre research_article
19 schema:inLanguage en
20 schema:isAccessibleForFree false
21 schema:isPartOf N523840d4723e4a7fbbf447350e205a53
22 N5cddb747f65945f8886aae9a38c64f02
23 sg:journal.1097576
24 schema:name What do the newer inotropic drugs have to offer?
25 schema:pagination 15-18
26 schema:productId N21c2366789c74017a8f002c9076127dc
27 N331dc11c2da641ab8578eb0bca3edbdc
28 N5a65bd461d3940edbd7f5cf3c404c295
29 N9bb8e23a29fa496bacd4c81b18c1aadb
30 N9e0fc5717e7844248f1a20e47895acae
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049995369
32 https://doi.org/10.1007/bf00050911
33 schema:sdDatePublished 2019-04-11T14:03
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher Nb4dccc2d0d444bdabed9243be877b843
36 schema:url http://link.springer.com/10.1007/BF00050911
37 sgo:license sg:explorer/license/
38 sgo:sdDataset articles
39 rdf:type schema:ScholarlyArticle
40 N164c33c229ac497cad11f74fdf7fb7fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
41 schema:name Administration, Oral
42 rdf:type schema:DefinedTerm
43 N21c2366789c74017a8f002c9076127dc schema:name pubmed_id
44 schema:value 1576092
45 rdf:type schema:PropertyValue
46 N331dc11c2da641ab8578eb0bca3edbdc schema:name readcube_id
47 schema:value ee294e3447a3c5f1f42da02524f11b0930a3ea0ebfc73f7c6b6adfde09aac546
48 rdf:type schema:PropertyValue
49 N4a13a1f9259b40689669825bf4f2e8fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Humans
51 rdf:type schema:DefinedTerm
52 N4c7ecb40a2524a6784e33091e72fb4da rdf:first sg:person.0771215563.82
53 rdf:rest rdf:nil
54 N523840d4723e4a7fbbf447350e205a53 schema:issueNumber 1
55 rdf:type schema:PublicationIssue
56 N5a65bd461d3940edbd7f5cf3c404c295 schema:name doi
57 schema:value 10.1007/bf00050911
58 rdf:type schema:PropertyValue
59 N5cddb747f65945f8886aae9a38c64f02 schema:volumeNumber 6
60 rdf:type schema:PublicationVolume
61 N94fb53b4a307446e8a9adf4a5c07f9a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Heart Failure
63 rdf:type schema:DefinedTerm
64 N9bb8e23a29fa496bacd4c81b18c1aadb schema:name nlm_unique_id
65 schema:value 8712220
66 rdf:type schema:PropertyValue
67 N9e0fc5717e7844248f1a20e47895acae schema:name dimensions_id
68 schema:value pub.1049995369
69 rdf:type schema:PropertyValue
70 Nb4dccc2d0d444bdabed9243be877b843 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 Ne14a1fcdb5c242cebc66d2903daec5b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Cardiotonic Agents
74 rdf:type schema:DefinedTerm
75 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
76 schema:name Medical and Health Sciences
77 rdf:type schema:DefinedTerm
78 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
79 schema:name Cardiorespiratory Medicine and Haematology
80 rdf:type schema:DefinedTerm
81 sg:journal.1097576 schema:issn 0920-3206
82 1573-7241
83 schema:name Cardiovascular Drugs and Therapy
84 rdf:type schema:Periodical
85 sg:person.0771215563.82 schema:affiliation https://www.grid.ac/institutes/grid.267346.2
86 schema:familyName Sasayama
87 schema:givenName Shigetake
88 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771215563.82
89 rdf:type schema:Person
90 sg:pub.10.1007/bf01857748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012082941
91 https://doi.org/10.1007/bf01857748
92 rdf:type schema:CreativeWork
93 https://app.dimensions.ai/details/publication/pub.1078806679 schema:CreativeWork
94 https://app.dimensions.ai/details/publication/pub.1079793544 schema:CreativeWork
95 https://doi.org/10.1016/0140-6736(90)91517-e schema:sameAs https://app.dimensions.ai/details/publication/pub.1053360172
96 rdf:type schema:CreativeWork
97 https://doi.org/10.1161/01.cir.69.2.298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016834176
98 rdf:type schema:CreativeWork
99 https://doi.org/10.1161/01.cir.71.5.963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049494226
100 rdf:type schema:CreativeWork
101 https://doi.org/10.1161/01.cir.82.3.774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003895734
102 rdf:type schema:CreativeWork
103 https://www.grid.ac/institutes/grid.267346.2 schema:alternateName University of Toyama
104 schema:name Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan
105 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...